Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460363 | 1.00 | KDM1A (0.53) | KDM1ASMN1; SMN2GHSRMGLLDPP4 | |
| SCHEMBL774880 | 0.85 | KDM1A (0.57) | KDM1A | |
| SCHEMBL20067709 | 0.84 | SMN1; SMN2 (0.65) | KDM1ASMN1; SMN2GHSRMGLL | |
| SCHEMBL20067667 | 0.84 | SMN1; SMN2 (0.65) | KDM1ASMN1; SMN2GHSRMGLL | |
| SCHEMBL21460337 | 0.83 | FASN (0.59) | KDM1A | |
| SCHEMBL21460333 | 0.83 | FASN (0.59) | KDM1A | |
| SCHEMBL4659511 | 0.81 | KDM1A (0.49) | KDM1A | |
| SCHEMBL14275540 | 0.81 | HSD17B10 (0.61) | MGLL | |
| SCHEMBL4223562 | 0.81 | HSD17B10 (0.61) | MGLL | |
| SCHEMBL2130912 | 0.80 | ACHE (0.60) | KDM1ASMN1; SMN2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | KDM1A 3238/4885SMN1; SMN2 2038/4885GHSR 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.